Earth Science Tech Inc. (ETST) Is Building on Unique Competitive Advantages to Deliver Steady Growth

• Earth Science Tech acquires, operates, optimizes, and manages autonomous revenue-generating divisions across pharmaceuticals, telemedicine, retail, and real estate development
• This approach has created a “conglomerate” business model that separates ETST from other healthcare companies and enables the company to capture the profit margins at every step that other companies are forced to outsource
• ETST’s competitive advantages include its end-to-end vertical integration that covers all aspects of patient care (consultation, pharmacies, and fulfillment) as well as the provision of B2B tech and real estate
• This vertical integration has resulted in direct revenue growth while continually building the company’s product pipeline

Earth Science Tech (OTC: ETST) has shown how its fundamental competitive advantages is able to build profit while serving its expanding base of customers more effectively. As a multifaceted and diversified holding company, ETST creates value by acquiring, operating, optimizing, and managing autonomous revenue-generating divisions across pharmaceuticals, telemedicine, retail, and real estate development. This strategy is baked in to the company’s “conglomerate” business model, which deviates from the traditional healthcare stock, insulating the company from sector-specific risks and shocks.

Within the healthcare domain, ETST is focused on building a vertically integrated platform that seamlessly integrates all aspects of patient care, from telemedicine (consultation) and pharmacy, through to fulfillment. With Peak Curative LLC, the company’s wholly owned subsidiary and telemedicine referral platform, ETST offers asynchronous consultations for Peak-branded compounded medications.

The Peak Curative telehealth platform enables users to discreetly explore various treatment options for things like weight loss and hair growth, connecting online users with licensed medical providers. The provider can approve necessary medication, with Peak Curative then shipping the products directly. These medications are prepared at RxCompound and Mister Meds, ETST’s wholly owned compounding pharmacies that aim to make prescription fulfillment fast and easy.

Similar efficiency is found in Miami-based RxCompound, providing bespoke medications not available from commercial manufacturers. RxCompound has developed an extensive range of affordable formulations designed to meet unique patient requirements. In addition, Texas-based Mister Meds serves as a licensed compounding pharmacy and hazardous drug handler.

RxCompound and Mister Meds are both synchronized into the company’s MOCTeledoc doctor network, creating a fully vertically integrated telehealth and pharmacy ecosystem. Accessible through MyOnlineConsultation.com, MOCTeledoc provides technology and clinical staffing solutions to digital health companies and helps clinics and third-party telemedicine platforms deliver efficient care. It represents an infrastructure-as-a-service tool that enables ETST to tap into the high-margin B2B revenue stream, powering the healthcare industry as a whole, rather than focusing solely on individual consumers (patients). Interestingly, this tool has the net effect of enabling ETST to actively profit by servicing its own competitors.

Besides empowering ETST to serve patients more effectively and generate revenue, the vertically integrated business model also helps feed the company’s product pipeline, as Giorgio R. Saumat, CEO and Chairman of the Board, explained in a BioMedWire Podcast episode (https://ibn.fm/VZSyE). “We always have research and development going on. The compounding pharmaceutical (space) is not your off-the-shelf kind of pharmaceutical products, so we’re always looking for something new. We have our doctors that are constantly suggesting new compounds for… sexual health, hair loss, or skincare. I know that right now, Peaks is working on an anxiety medication. We have a very good pulse into where the healthcare community is going when it comes to health and wellness,” said Mr. Saumat. “I think our pipeline is strong and as we continue to diversify and build on these products, we’ll see the results of that,” he added. 

The expected results Giorgio referenced in his forward-looking statement will build on the progress recorded in Earth Science Tech’s fiscal year-end 2026 results (https://ibn.fm/ZlM3k). The company’s revenue grew 8% year over year, while gross profits and net income increased 5% and 11%, respectively. According to Mr. Saumat, these results were driven “by the work we have done to better integrate the patient experience across our platform….”

ETST’s end-to-end vertical integration means that it owns the healthcare ecosystem, relies on its in-house B2B tech stack, provides a proprietary doctor network to competitors, controls the supply chain (from the manufacture of medications to shipping), and owns real estate through its Avenvi subsidiary. As a result, Earth Science Tech captures the profit margins at every step that other companies are forced to outsource.

For more information, visit the company’s website at www.EarthScienceTech.com.

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at  https://ibn.fm/ETST

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN